XVIVO Perfusion AB
21.10.2021 08:06:47 CEST | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / October 21, 2021 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)
Third quarter 2021 (Jul 1 - Sep 30)
• Net sales amounted to SEK 54.9 million (42.7), corresponding to an increase of 29 percent in SEK and 31 percent in local currencies.
• Net sales of non-durable goods amounted to SEK 48.9 million (42.3), corresponding to an increase of 16 percent in SEK and 18 percent in local currencies.
• Sales growth for the quarter consisted entirely of revenue from the Abdominal business area, which was not included in the comparison quarter. For Thoracic, sales for the quarter were in line with the previous year's quarter.
• Machine perfusion accounted for 53 percent (41) of net sales.
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 5.3 million (9.3), corresponding to an adjusted EBITDA margin of 10 percent (22). Reported EBITDA amounted to SEK 4.2 million (-11.2), corresponding to an EBITDA margin of 8 percent (-26).
• Adjusted operating profit (EBIT) amounted to SEK -2.9 million (1.8). Reported EBIT amounted to SEK -4.0 million (-18.7).
• Net profit amounted to SEK -1.1 million (-14.7). Earnings per share amounted to SEK -0.04 (-0.51).
• Cash and cash equivalents at the end of the quarter amounted to SEK 284.5 million (608.4).
Significant events during the quarter
• Strategic focus areas were presented at XVIVO's first Capital Markets Day. These will support the company's goal to become the leading player in the transplant industry during the strategy period 2022-2026.
• XVIVO participated with a strong presence at the ESOT Congress in Milan. The focus of the congress on machine perfusion was very evident.
• A pilot project in advanced data analysis from liver perfusion was initiated with UMC Groningen as a partner.
The period 2021 (Jan 1 - Sep 30)
• Net sales amounted to SEK 172.5 million (119.6), corresponding to an increase of 44 percent in SEK and 54 percent in local currencies. Net sales of non-durable goods amounted to SEK 160.0 million (114.5), corresponding to an increase of 40 percent in SEK and 50 percent in local currencies.
• Machine perfusion accounted for 52 percent (36) of net sales.
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 20.0 million (13.4), corresponding to an adjusted EBITDA margin of 12 percent (11). Reported EBITDA amounted to SEK 13.9 million (-9.1), corresponding to an EBITDA margin of 8 percent (-8).
• Adjusted operating profit (EBIT) amounted to SEK -4.1 million (-8.8). Reported EBIT amounted to SEK -10.2 million (-31.3).
• Net profit amounted to SEK -4.0 million (-24.2). Earnings per share amounted to SEK -0.14 (-0.91).
• Cash and cash equivalents at the end of the period amounted to SEK 284.5 million (608.4).
Significant events in the period
• Publication in reputable scientific journal The New England Journal of Medicine shows significant benefits of oxygenated cold machine perfusion prior to liver transplantation.
• The 510(k) application for Kidney Assist Transport was submitted to the FDA.
• Guidelines from NICE supporting EVLP as the standard lung preservation procedure were issued in the UK.
CEO comment
"XVIVO had an eventful and intensive third quarter. In August, the company launched a new strategy for the coming five years to support our goal of becoming the global leader in the transplantation industry for all major organs. Abdominal made its strongest sales quarter for the year while Thoracic showed a decline, attributable to a temporarily reduced number of lung transplants in the US. We expect a gradual increase in the number of transplants in all markets as the number of new Covid-19 cases decreases and in our main market, the US, September and October have shown positive trends."
Conference call
CEO Dag Andersson och CFO Kristoffer Nordström will present the report in a conference call today at 2 PM CET. Telephone UK: +44 333 300 0804, USA: +1 631 913 1422 or Sweden: +46 8 566 426 51 PIN: 13466713#
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-10-21 07:30 CEST.
SOURCE: XVIVO Perfusion AB
View source version on accesswire.com:
https://www.accesswire.com/669059/XVIVO-Presents-Interim-Report-January-September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release
Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key
Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization29.1.2026 14:30:00 CET | Press release
Innodata's data engineering and annotation capabilities support Palantir's expanding AI platform deployments for event analytics NEW YORK, NY / ACCESS Newswire / January 29, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it has been selected to provide high-quality training data and data engineering services to Palantir Technologies (Nasdaq:PLTR), supporting Palantir's AI-enabled platforms for rodeo event analysis. In support of Palantir's partnership with rodeo operations, Innodata is now further empowering these customers by providing them with specialized annotation and data engineering for thousands of hours of rodeo video footage. This work enables computer vision models to detect animals, riders, and skeleton joints, allowing for the automated calculation and display of performance metrics in bull riding, bronc riding, bareback riding and barrel racing. Innodata will be providing specialized annotation, multimodal data engineering, and generative-AI workflow support for
Sadie Launches Cloudbeds Integration to Automate Guest Calls and Reservation Management with Voice AI28.1.2026 17:25:00 CET | Press release
MONTRÉAL, QUEBEC / ACCESS Newswire / January 28, 2026 / Sadie, the voice AI agent for the hospitality industry, today announced a new integration with Cloudbeds, the hospitality industry's leading unified platform, enabling hotels to automate guest calls while increasing direct bookings and freeing staff to focus on on-property service. Through the integration, Cloudbeds-powered hotels can deploy Sadie as an intelligent voice agent that answers calls instantly, shares real-time rates and availability, and creates and manages reservations directly within the Cloudbeds platform. Designed as an always-on extension of the front desk, Sadie ensures guest calls are answered instantly, day or night. From sharing real-time rates and availability to creating and modifying reservations, handling service requests, and assisting with overnight room lockouts, Sadie delivers immediate, multilingual support for both guests and hotel teams. By handling high-volume and after-hours calls, Sadie reduces
Power to Hydrogen Appoints David Bow as Chief Strategy Officer to Scale International Expansion28.1.2026 15:00:00 CET | Press release
Industry Veteran Brings 25+ Years Of Senior Leadership In Hydrogen And Industrial Decarbonization COLUMBUS, OH / ACCESS Newswire / January 28, 2026 / Power to Hydrogen (P2H2), a developer of industrial-scale anion exchange membrane (AEM) electrolyzers designed for low-cost green hydrogen production, today announced that industry veteran David Bow has joined the company as Chief Strategy Officer. Bow will lead P2H2's corporate and commercial strategy as the company expands its industrial deployments and scales its go-to-market efforts in North America and Europe. His scope includes strategic partnerships, market entry and segmentation, commercial growth priorities, and alignment of product roadmap and validation plans with customer and financing requirements. Bow brings more than 25 years of senior leadership experience across hydrogen and industrial energy, including executive roles spanning commercialization, strategy, and scaling. He previously led Plug Power's Electrolyzer Solutions
GoodData Brings Faster BI Modernization to Make Analytics AI-Ready28.1.2026 15:00:00 CET | Press release
Modernize legacy BI without disruption. Refactor business logic into a governed semantic layer while keeping dashboards online. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 28, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today introduced AI-driven BI modernization, a new approach that helps organizations move off legacy BI faster while preserving critical reporting workflows. Early outcomes teams can expect AI-driven BI modernization separates business logic from dashboards and standardizes it in a governed semantic layer. This improves performance today and creates a stronger baseline for AI-driven use cases tomorrow. Expected results include: 2-5× faster iteration cycles for delivering new analytics Dashboards that load up to 10× faster by removing inefficient calculations and duplication Consistent, reusable metrics governed centrally and applied across teams and tools AI-ready analytics with clean, standardized logic that AI agents and aut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom